aktuell

The global Sperm Bank Market has been witnessing increasing growth since the last few recent years, primarily owing to the surge in social acceptance and awareness among the general population. Rise in the number of young sperm donors, legalization of and increase in same-sex marriages, various technological advancements in the field of assistive reproduction, and strong support on the part of governments toward donor offspring and sperm donors are also projected to boost the sperm bank market. However, this market continues to be challenged by the negative mindset toward sperm donation, high cost of artificial insemination and assistive reproduction, and several government regulations in developing and underdeveloped countries.

Sperm donors can be of several types: Directed donor, client donor, anonymous donor, and known donor. Sperm banks offer a range of services such as sperm storage, genetic consultation, sperm donations, and semen analysis for a variety of end users such as pre-vasectomy patients, police officers, high-impact athletes, cancer patients, military personnel, firefighters, and transgender people.

The report on the global sperm bank market offers clients an in-depth assessment of the emergence, popularity, need, and forecast of sperm banks across the globe. Various factors driving the demand for sperm banks, those that act as impediments to the market growth, and several policies and laws impacting sperm donation as a service have been carefully studied in the report. The research also highlights the present status of the vendor landscape, identifying the major players competing at a global level and evaluating their performance over the years.

Request to View Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12173

Global Sperm Bank Market: Region-wise Outlook

The global sperm bank market has been segmented on the basis of geography into North America, Europe, Asia Pacific, and Rest of the World. Considering that North America has the highest number of sperm banks with the highest number of licensed labs, this regional market for sperm banks is one of the largest in the world. Other factors such as the availability of advanced assisted reproductive technologies, higher disposable income and spending on health care, growing awareness among the general population, and high rate of miscarriages have also significantly contributed to the growth of the sperm bank market in North America.

Europe is a growing market for sperm banks given the surging demand for the same. However, the high unmet need is presently the only lucrative attraction for market players in the region, since there is a severe shortage of sperm donors as compared to the increasing demand. Countries such as the U.K. have been investing in new and innovative advertising plans to increase awareness among the male population in the country and encourage them to actively participate in sperm donation.

The sperm bank market in Asia Pacific holds immense opportunities owing to a high rate of infertility and miscarriages in the region. In China, For instance, the alarming levels of air pollution in China have caused a decrease in sperm quality, count, and motility, thereby driving the demand for sperm donors and sperm banks.

Global Sperm Bank Market: Vendor Landscape Assessment

The vendor landscape of the global sperm bank is consolidated to an extent, considering very few large players control a majority of the overall sperm bank market. New England Cryogenic Center Inc., Cryos International Sperm Bank, FairFax Cryobank, and Androcryos are currently the most prominent and dominant companies operating in the global sperm bank market. Orlando, a Florida-based Cyros International Sperm Bank, is presently one of the largest sperm banks in the world. With an additional base set up in Mumbai, India in 2008, Cryos has been approved by the U.S. Food and Drug Administration as well as the Indian Council of Medical Research. Recognizing the immense potential that the sperm bank market possesses, an increasing number of players have been undergoing continuous upgrade to withstand the competition presented by industry giants.

Enquiry for discount on this report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=12173

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Peripheral arterial disease, also known as peripheral vascular disease is a condition in which the arteries, other than supplying blood to heart and brain narrow down. Peripheral arterial disease mostly affects the legs, though other arteries may also be involved. Peripheral arterial disease is caused by the deposition of fats (plaques) in the artery walls which reduce the blood flow to organs, limbs and head. The population over the age of 50 are at the risk of suffering from peripheral arterial disease. The growing geriatric population, increasing therapies, rising minimally invasive techniques support the growth for Peripheral Arterial Disease Market. It has been estimated that globally around 20% of the total population above the age of 60 years are affected by peripheral arterial diseases. High risk factors such as smoking and diabetes contributes towards increase in incidence rate of peripheral arterial diseases which would stimulate the growth of peripheral arterial disease market globally.

The peripheral arterial disease therapeutic market has been segmented into devices, drugs and pipeline. The devices segment is further categorized into devices such as peripheral vascular stents, peripheral transluminal angioplasty balloon catheters, PTA Guidewires, atherectomy devices, chronic total occlusion devices, aortic stents, synthetic surgical grafts, embolic protection devices and inferior vena cava filters. The peripheral vascular stents accounts for the largest share, followed by peripheral transluminal angioplasty balloon catheters. While emnolic protection devices are the fastest growing segment in the global peripheral arterial disease therapeutic market. The drugs segment can be segmented on the basis of cholesterol-lowering drugs, high blood pressure lowering drug, blood sugar regulating drug, and blood clot preventing drug. The phase III pipeline drugs for peripheral arterial disease include Rivaroxaban (Bayer), DLBS1033 (Dexa Medical Group), clopidogrel (SR25990) (Sonofi), Propionyl-L-Caritine (Sigma-Tau Research, Inc.) and others.

Geographically, peripheral arterial disease therapeutic market has been segmented in North America, Europe, Asia Pacific, Latin America and Rest of the World (RoW). North America, accounted for the largest share in the overall peripheral arterial disease therapeutic market. The dominance is majorly due the high adoption rates of minimally invasive surgeries, higher healthcare expenditure and patient awareness, making North America the leading market for peripheral arterial disease therapeutic market. Europe accounted for the second largest market for peripheral arterial disease therapeutic market. The aging population would boost the demand for peripheral arterial devices in the forecast period. Asia Pacific is anticipated to be the most lucrative market for peripheral arterial disease therapeutic market.

Request to View Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=9506

The major factors attributing the fastest growth of this region is the presence of large patient pool with unmet medical needs, acting as the opportunity for the players operating in this market. Growing healthcare scenario in the Asian countries coupled with the growing GDP and government initiative would assist the market growth for peripheral arterial disease therapeutics market. South American countries such as Brazil and Mexico are the regions that have significant potential for growth due to developing medical infrastructure, high disposable income and rising prevalence of peripheral arterial disease in the region assisting the market growth. The Rest of the World includes countries such as Russia and countries of Middle East and Africa. The market for peripheral arterial disease therapeutic is subject to grow due to the improving government initiative and rising awareness.

Some of the major players operating in the peripheral arterial disease therapeutics market are Abbott Laboratories, Angioscore, Inc., Edward Lifesciences Corporation, Medtronic Inc., Boston Scientific Corporation, Bayer, Volcano Corporation, Sanofi S.A. and others.

Enquiry for discount on this report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=9506

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Hydrocodone bitartrate is often used to relieve severe ongoing pain. It belongs to the narcotic (opiate) analgesic class of drugs. It affects the functioning of the brain by altering how the body responds to pain. Hydrocodone Bitartrate is generally prescribed for oral ingestion as narcotic aanalgesic and antitussive. It is often given in combination with ibuprofen or acetaminophen. The Administrative Controlled Substance Code Number (ACSCN) for hydrocode is 9193. Medical applications where hydrocodone bitartrate is used to relive pain is the largest application for Hydrocodone Bitartrate. The sale of hydrocodone bitartrate is regulated in various countries since there can be chances of substance abuse.

The demand for hydrocodone bitartrate for medical applications is expected to witness strong growth in the next few years. Hydrocodone bitartrate use in cough treatment is anticipated to be the major application in the near future. The ingestion of hydrocodone bitartrate can cause several side effects such as dizziness, nausea, lightheadedness, sedation, vomiting and constipation. The sale of hydrocodone bitartrate is regulated in many countries, the sale is banned in countries such as Belgium, France, Germany, Sweden etc. It is classified as List 1 drug under the Opium Law in Netherlands. The sale of hydrocodone bitartrate for medical use is also banned in United Kingdom, where it is listed as a Class A drug under Misuse of Drugs Act 1971.

However, weaker formulation of hydrocodone bitartrate is being used as an alternative in various medical applications. In the U.S. hydrocodone bitartrate is subject to annual manufacturing quota. However, hydrocodone bitartrate is not commercially available in its purest form. It is generally sold with a NSAID, antihistamine, acetaminophen, homatropine or expectorant. Overdose of hydrocodone bitartrate include effects such as widened pupils, shallow, slow or stopped breathing, stopped or slowed heartbeat, clammy, cold or blue skin excessive sleepiness. In certain cases over dosage can also have fatal effects. Hydrocodone bitartrate usage in cough syrup in combinations with other chemicals is expected to one of the major applications in the next few years.

Request to View Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3765

In terms of demand North America was the largest consumer of hydrocodone bitartrate followed by Asia Pacific, Europe and Rest of the World. In North America U.S was the largest Hydrocodone Bitartrate Market followed by Mexico and Canada. This high demand for hydrocodone bitartrate stems from the growing demand for medical treatment applications in this region. The demand for hydrocodone bitartrate is also projected to witness strong growth in Asia Pacific due to non present regulations in this region. The demand for hydrocodone bitartrate is anticipated to witness strong growth in the Asia Pacific countries such as China, India, Indonesia etc. With growing population in these regions the demand for hydrocodone bitartrate is also expected to grow on similar lines. The economic conditions of Brazil, Russia and South Africa are on similar track and hence the demand for hydrocodone bitartrate is also projected to be high in these countries. The sale of hydrocodone bitartrate is banned is several European countries such as Germany, Sweden, France Belgium, United Kingdom etc. It sold under certain regulation in countries like Netherlands.

Some of the major companies operating in the global hydrocodone bitartrate market are Xi\’an Jbiotree Industrial Co., Ltd., Ranbaxy Pharmaceuticals Inc., Ausmauco Biotech Co. Ltd. and AbbVie Inc. among others.

Enquiry for discount on this report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=3765

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Rhinitis is an acute disease of the nasal system. Rhinitis is the irritation and inflammation of the internal lining and mucous membrane of the nose. The rhinitis is one of the short term and environment related disorders, which is identified by common symptoms, such as, runny nose, stuffy nose and post-nasal drip.

Among various types of rhinitis, allergic rhinitis is the most common disease. Allergic rhinitis, as the name indicates, occurs due to various allergy propelling factors, such as, pollen grains, dust, mist, fog, and other airborne allergens. When these allergens are inhaled by immune-sensitive person, it triggers the production of IgE (immunoglobulin E antibody). IgE triggers the histamine secretion, which leads to irritation and inflammation of mucous membrane. Perennial allergic rhinitis is the most common and frequently occurring type of allergic rhinitis.

The major symptoms of the disease include itching, sneezing, rhinorrhea, nasal obstruction and congestion. Sometimes, rhinitis may occur due to chronic diseases, such as, asthma, eczema and depression. The causes of the disease include pollens and airborne allergens of various natural origin, such as, trees, weeds and grasses. The disease is diagnosed by using Radio Allergo Sorbent Testing (RAST) blood test, skin test (patch test), skin prick test, and allergen sensitivity test.

The Perennial Allergic Rhinitis Market is segmented on the basis of drugs classes used for the treatment, such as, steroids, antihistamines, allergen immunotherapy formulations, decongestants, and other complimentary treatments. Steroids class mainly includes intranasal corticosteroids, prednisolone, beclometasone, and triamcinolone acetonide. Whereas, antihistamines class include citrizine, chlorphenamine, promethazine, acrivastine, loratadine and others. Allergen immunotherapy formulations mainly include desensitizing vaccines. Decongestants mainly include phenylephrine hydrochloride and others. Other treatments include cromolyn formulations (sodium cromoglycate as anti-inflammatory agent), leukotriene receptor antagonists and others. Further, the market is segmented on the basis of geography, such as North America, Europe, Asia-Pacific and Rest of the World (RoW). The European region is the most dominating market in the world, owing to large number of perennial allergic rhinitis diagnosed patients. On the other hand, Asia-Pacific and RoW regions are the most promising markets in upcoming period, owing to rising awareness and treatment of disease and rising prevalence of disorder, and growth of medical infrastructure.

Request to View Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2936

The market of perennial allergic rhinitis is expected to show steady growth during the forecast period 2014 – 2020. This growth is driven by various factors, such as extensive R&D practices to develop new and more effective products and formulations, rising number of patients, changes in lifestyle and other environmental conditions. These factors are coupled with rising awareness about the disease and its diagnosis. According to World Allergy Organization (WAO), the prevalence of allergic rhinitis varies from 1.4% to 40% in various countries of the world. European and APAC countries are the most prevalent to disease, due to frequently varying environmental and climatic conditions. According to American College of Asthma, Allergy and Immunology (ACAAI), in 2010, around 16.9 million adults and 6.7 million children were diagnosed with hay fever. This high prevalence of the disease is anticipated to propel the growth of the market during the forecast period 2014 – 2020. Further, due to extensive R&D practices, a number of new formulations for the treatment of perennial allergic rhinitis are under pipeline studies. For instance, formulations like S-555739, desloratadine, GMNL-32 and many others are under pipeline studies and are expected to enter in the market during upcoming 5-10 years.

Hence, this fact is expected to fuel growth of the market. Major restraints include ignorance towards the disease and side effects of the therapy, which may limit the growth of the market to certain extent.

Some of the major players operating in this market include Pfizer, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Hanmi Pharmaceuticals, Inc. amongst others.

Enquiry for discount on this report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2936

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

A biomarker is any cellular, physical, chemical, or molecular change that can be noted and a normal or abnormal process in human body can be studied. The effects of treatment, the presence, progress or risk for a disease can be checked by studying any alteration in the normal amount of a biomarker. A tumor marker, like a biomarker, is a naturally occurring substance in the body. An increased quantity of a tumor marker can show the presence of a cancer. Some tumor markers are related to several different types of cancer, while some are specific to one type of cancer. Tumor markers may also increase with non-cancerous conditions. A tumor marker can be prepared by cancer cells or by the body in response to cancer.

There are many different types of tumor markers such as human chorionic gonadotropin (HCG or b-HCG), cancer antigen 15-3 (CA15-3), alpha-fetoprotein (AFP), carbohydrate antigen 19-9 (CA19-9), cancer antigen 125 (CA125), carcinoembryonic antigen (CEA), and prostate-specific antigen (PSA). Tumor markers can provide information that can be used for screening for cancer, diagnose cancer, determine stage of cancer, determine a person’s prognosis, guide treatment, monitor treatment, and determine recurrence of the cancer. Some markers can be used in people with family history of a particular cancer. Prostate specific antigen can be used to screen for prostate cancer. Tumor markers can be used to help determine how far the cancer has spread into other tissues or organs. Some markers are used to determine how aggressive a cancer is likely to be. Some markers may help doctors predict what treatments the cancer is likely to respond to.

A tumor marker test is done to make available a baseline level before treatment, when any type of cancer is suspected, to check if cancer has returned after treatment being given, and to check a person’s reaction to cancer treatment. Tumor markers are molecules found in urine, blood, and body tissues. It is a protein found in large amounts in presence of cancer. Hence, measuring the levels of tumor markers may help in detecting the presence of cancer. Presence of a tumor in body stimulates the production of tumor markers from tumor or non-tumor cells. The Tumor Marker Testing Market has been categorized based on diagnostic method, type of cancer, and technology employed for cancer detection. Organ specific tumor marker: bladder, breast, colorectal, gastrointestinal, liver, lung, oral, ovarian, pancreatic, prostatic, skin testicular cancer, leukemia, lymphoma, and others; Clinical laboratory methods for measuring tumor markers: Abbott diagnostics’ AxSYM, Roche Diagnostics System, Fischer Thermo Scientific B.R.A.H.M.S KRYPTOR and others; New technologies for cancer diagnostics: Monoclonal antibodies, proteomics, new protein markers, stem cell markers, DNA microassays and others; Clinical methods for cancer diagnosis: Screening, imaging, theranostics, sigmoidoscopy and others.

Request to View Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2253

Currently, cancer is the one of the leading causes of death in North America and Europe. North America holds the largest share of the tumor marker testing market, followed by Europe, due to vast discoveries and innovations for detecting cancer in early stages. Major factors driving the tumor marker testing market in these regions are rising incidence of cancer disease, increase in geriatric population, ongoing research in the field of cancer detection, and improved government reimbursement policies. However, high cost acts as a major restraint of the market.

Geographically, North America held the larger market share, followed by Europe. High research on tumor marker and increasing number of cancer patients in these regions are likely to boost the tumor marker testing market. However, affordability has become a restraining factor in this market in developing regions such as Asia Pacific and Latin America. However, the tumor marker testing market in Asia Pacific is expected to experience strong growth.

Major players in the tumor marker testing market are Abbott Diagnostics Ltd., Affymetrix, Inc., Agilent Technologies, Inc., Beckman, Dickinson and Company (BD) Diagnostics, BioCurex, BioModa, Inc., Clarient, Inc., Correlogic Systems, Inc., Epigenomics AG, Gen-Probe, Inc., Hologic, Inc., Roche Diagnostics Corp., and Veridex LLC, among others.

Enquiry for discount on this report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2253

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Physician office lab (POL) term is wide and diverse, it encompasses physician’s practices as small (2 to 5 doctors) to large practitioners (200 physicians) that operate labs similar to small laboratory hospitals. Hospitals and commercial labs perform tests, but physicians prefer to perform in-house testing in order to enhance the patient care. In-house testing facilitates physicians to no longer rely on the reference labs for test results. In addition, physicians can obtain faster results from their own labs and increase profits. POL also reduces the chances of loss or deterioration of the sample. Therefore, definition of POL is broad and it refers to the test performed in: physician office setting, provides a result during medical visit, conducted at the time of consultation or with other healthcare professional and is used for diagnosis, screening or monitoring purposes.

In addition global Physician Office Laboratory Testing Market is increasing owing to rise in infectious diseases and the associated public health issues with increasing cardiovascular and other chronic conditions. Moreover, increasing trends of preventive medicine and proactive approach in treating the increasing number of diabetic patients is also accentuating the market size.

Advancements in technology is favoring the market growth, as new microelectronic and microfluidic instruments that are small, easy to use and offer excellent quality and control. The compact size of many lab instruments has made POL feasible for even smaller offices and has enabled some physician to even perform test for other doctors. Therefore, physicians who want to access the test results immediately are setting up POL’s.

Request to View Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1731

North America represents the largest market where number of POL’s grew from 95,069 in 2000 to 111,000 in 2010. The FDA has approved many tests such as spun microhematocrit, monitoring instruments, nonautomated testing for erythrocyte sedimentation and other various tests. In addition there are more than 9 tests which are yet to be approved by FDA.

POL’s streamlines the doctors testing procedure by reducing time, increase patient efficiency and also positively impact staff efficiency. POL also provides fast turn around time of results and hence enables review of results face to face with the patient. All these factors collectively contribute to the growth of POL’s testing market.

Some of the key players in POL market include 3D Medical Diagnostics, Accumetrics, Biomerica, Inc., Nanosphere, Inc. and other significant players.

Enquiry for discount on this report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1731

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com